Prospective randomised controlled trial of: MRSA Prophylaxis for lower limb amputation - Amputation trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-001701-97-GB

Enrollment

480

Registered

2005-11-07

Start date

2005-12-20

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operative MRSA infection following lower limb amputation

Interventions

Product Name: Targocid Product Code: PL 04425/0089 & PL04425/0090 Pharmaceutical Form: Powder for injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients undergoing major lower limb amputation (below knee, through knee, or above knee) for peripheral vascular disease will be selected for the study. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients unable to give informed consent (dementia or severly ill). Those patients undergoing urgent or emergency amputation where adequate time has not been available to gain informed consent for participations in the trial (less than 24 hours).

Design outcomes

Primary

Measure	Time frame
Main Objective: To assess whether MRSA prophylaxis in pateints undergoing lower limb amputation prevents post-operative MRSA infection.;Secondary Objective: Time to wound healing, days in hospital, need for revision surgery and death;Primary end point(s): Primary wound healing. Post operative wound MRSA infection	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026